@article{575fc6fbb7fa4819a7cf41806bdb13c8,
title = "Association of arterial pulse pressure with long-term clinical outcomes in patients with heart failure",
abstract = "Objectives: This study assessed the association between pulse pressure (PP) and adverse outcomes at 1 year in patients hospitalized for heart failure (HF). Background: PP has been shown to be predictive of the development of HF. The value and utility of PP assessment in patients with prevalent HF is less clear. Methods: We conducted a retrospective cohort study from clinical registry data linked to Medicare claims for 40,421 HF patients entered in the Get With the Guidelines-HF program. Cox proportional hazards models were used to estimate the association between discharge PP and all-cause mortality and the composite outcome of all-cause mortality/readmission by 1 year. Results: A nonlinear association between PP and mortality (expressed as hazard ratio [HR] per 10-mm Hg increase in PP) was observed in patients with HF and reduced (<0.40) ejection fraction (EF). Risk decreased as PP increased up to 50 mm Hg (adjusted HR: 0.946; 95% confidence interval [CI]: 0.900 to 0.995; p = 0.03). When PP was ≥50 mm Hg, risk increased as PP increased (adjusted HR: 1.091; 95% CI: 1.050 to 1.135; p < 0.001). In patients with HF and preserved EF (≥0.40), there was a significant association between PP and mortality with risk increasing as PP increased, although the magnitude of the risk was significantly impacted by systolic blood pressure (SBP). Qualitatively similar observations were obtained for the composite outcome and use of EF ≥0.50 to define HF with preserved EF. Conclusions: The association between PP at hospital discharge and 1-year outcomes is a function of HF phenotype, SBP, and absolute PP.",
keywords = "Heart failure, Pulse pressure",
author = "Laskey, {Warren K.} and Jingjing Wu and Schulte, {Phillip J.} and Hernandez, {Adrian F.} and Yancy, {Clyde W.} and Heidenreich, {Paul A.} and Bhatt, {Deepak L.} and Fonarow, {Gregg C.}",
note = "Funding Information: Get With the Guidelines-Heart Failure, sponsored by the American Heart Association, has been supported by Medtronic, GlaxoSmithKline, Ortho-McNeill, and the American Heart Association Pharmaceutical Roundtable. Dr. Hernandez has received research support from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, and Novartis and honoraria from Amgen, Bristol-Myers Squibb, Novartis, and Janssen. Dr. Bhatt is on the advisory boards of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; and on the board of directors of Boston Veterans{\textquoteright} Affairs Research Institute and Society of Cardiovascular Patient Care; serves as Chair, American Heart Association{\textquoteright}s Get With the Guidelines-Heart Failure Steering Committee; is a member of the Data Monitoring Committees for Duke Clinical Research Institute, Harvard Clinical Research Institute, and Mayo Clinic Population Health Research Institute; has received honoraria from American College of Cardiology as Senior Associate Editor, Clinical Trials and News, Belvoir Publications as Editor in Chief, Harvard Heart Letter, and from Duke Clinical Research Institute, serving on clinical trial steering committees, Harvard Clinical Research Institute clinical trial steering committee, HMP Communications as Editor in Chief, Journal of Invasive Cardiology, Journal of the American College of Cardiology as Associate Editor and as Section Editor, Pharmacology, Population Health Research Institute clinical trial steering committee, Slack Publications as Chief Medical Editor, Cardiology Today{\textquoteright}s Intervention, WebMD CME steering committees, and Deputy Editor of Clinical Cardiology; has received research funding from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, The Medicines Company; and support from FlowCo, PLx Pharma, and Takeda. Dr. Fonarow has received research support from Agency for Healthcare Research and Quality, and U.S. National Institutes of Health; and is a consultant for Amgen, Bayer, Gambro, Janssen, Novartis, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2016 American College of Cardiology Foundation.",
year = "2016",
month = jan,
day = "1",
doi = "10.1016/j.jchf.2015.09.012",
language = "English (US)",
volume = "4",
pages = "42--49",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "1",
}